Clinical and Biochemical Presentation of Polycystic Ovary Syndrome in Different Age Group

November 4, 2013 updated by: Ming-I Hsu, Taipei Medical University WanFang Hospital

To study the clinical and biochemical characteristics women with polycystic ovary syndrome (PCOS) in different aged groups.

Study Overview

Status

Completed

Conditions

Polycystic Ovary Syndrome

Detailed Description

Polycystic ovarian syndrome (PCOS) is the most frequent endocrine disorder of reproductive age women, affecting an estimated 9-18% of all women in this age group. To diagnose of PCOS in early life is especially important because it is now thought to increase metabolic and cardiovascular risks. Investigating PCOS is crucial as it is now considered to increase metabolic and cardiovascular risk, thereby impacting the health of women to a much greater extent than previously thought. We are plan using retrospective analysis to evaluate the clinical and biochemical presentation of PCOS in different aged groups.

Study Type

Observational

Enrollment (Actual)

781

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Taiwan
- - Taipei, Taiwan
    - Taipei Medical University-WanFang Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 46 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Reproductive age women

Description

Inclusion Criteria:

Reproductive age women with sufficient data

Exclusion Criteria:

Disorders of uterus (e.g. Asherman's Syndrome, Mullerian agenesis) and chromosomal anomalies (e.g. Turner syndrome)
women who had had menarche at less than 3 years of age, Day 3 FSH > 15, or who were older than 46
women with inadequate clinical/biochemical records
and women who had had ovarian cysts or ovarian tumors in ultrasonography examination
pregnancy women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Number of groups / cohorts

Cohorts and Interventions

Group / Cohort
Control Group
Experimental Group

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Taipei Medical University WanFang Hospital

Investigators

Principal Investigator: Ming-I Hsu, Taipei Medical University WanFang Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2011

Primary Completion (Actual)

April 1, 2012

Study Completion (Actual)

April 1, 2012

Study Registration Dates

First Submitted

May 9, 2011

First Submitted That Met QC Criteria